Systemic cancer (the dissemination and subsequent distant outgrowth of cells from a solid tumour) occurs in two phases: a clinically latent stage of hidden cancer spread, and then manifest metastasis. Manifest metastasis remains mostly incurable. The period of clinically unde tectable minimal residual disease, defined by disseminated cancer cells (DCCs) that are left behind after primary tumour surgery, offers a time window to prevent metastasis 1, 2 . However, only circumstantial know ledge is available about minimal residual disease, and consequently, systemic (adjuvant) therapies improve outcome in only about 20% of patients 3, 4 . This situation indicates that our current understanding of early systemic cancer is insufficient to prevent metastasis.
The first direct evidence for a characteristic biology of early dis seminated cancer and minimal residual disease came from analyses of DCCs isolated from bone marrow of patients with breast cancer before (M0 stage, according to Union for International Cancer Control guidelines) and after (M1 stage) manifestation of metastasis 5, 6 , indi cating that M0DCCs might have disseminated early and evolved in parallel with the primary tumour 7 . Studies in transgenic mouse models [8] [9] [10] and in patients with premalignant lesions or in situ carcinomas 8, 11, 12 corroborated this concept but the relevance of DCCs remains contested 13 .
We therefore addressed the issue of breastcancercell dissemina tion soon after cancer initiation and investigated whether mechanisms exist that reduce metastatic seeding from advanced cancers. Finally, we investigated whether early DCCs (eDCCs) are able to form metastases. We report on a mechanism involving cell density, HER2 and PGR signalling that reconciles early and late dissemination models.
PGR and HER2 regulate gene expression in early lesions
In BALBNeuT mice, dissemination starts shortly after expression of the Her2 transgene (also known as Erbb2) at puberty (around 4 weeks of age), when the first hyperplastic lesions become apparent 8 . From 4-9 weeks of age, we observed microinvasion 8 , and a sharp decline in the ratio of DCCs to total tumour area (a measure of cell numbers at risk of disse mination) during primary tumour growth (Extended Data Fig. 1a ). The genetic program governing dissemination from early lesions in micro dissected tissue samples (Extended Data Fig. 1b and Supplementary Table 1 ) showed a signature gene expression profile compared to healthy mam mary glands, primary tumours and lung metastases ( Fig. 1a ). We defined 1,278 gene transcripts unique to early lesions of which 300 were highly conserved between mouse and human (Supplementary Data 1).
We confirmed differential expression of selected transcripts by quan titative PCR (qPCR) (Extended Data Fig. 1c ) and analysed transcript expression of steroid hormone receptors (strong candidate regulators; Supplementary Tables 2, 3) , all of which, except Esr1 (also known as ERalpha), showed the highest expression in early lesions (Extended Data Fig. 1d ). When we assessed the expression of Ahnak, Baz2a, Nfatc3, Nr3c1 and Nr3c2 genes, which were used as surrogate markers of the early lesion signature ( Fig. 1b , Supplementary Tables 2, 3 and Supplementary Data 1), progesterone was the only steroid hormone that activated a similar expression profile (Extended Data Fig. 1e ), but only in early lesion cells of 9weekold BALBNeuT mice, and not in wildtype mammary or primary tumour cells (Fig. 1c) . Moreover, the expression of progesterone receptor B (PGRB), which is the main isoform expressed for mammary gland development 14-16 , correlated Accumulating data suggest that metastatic dissemination often occurs early during tumour formation, but the mechanisms of early metastatic spread have not yet been addressed. Here, by studying metastasis in a HER2-driven mouse breast cancer model, we show that progesterone-induced signalling triggers migration of cancer cells from early lesions shortly after HER2 activation, but promotes proliferation in advanced primary tumour cells. The switch from migration to proliferation was regulated by increased HER2 expression and tumour-cell density involving microRNAmediated progesterone receptor downregulation, and was reversible. Cells from early, low-density lesions displayed more stemness features, migrated more and founded more metastases than cells from dense, advanced tumours. Notably, we found that at least 80% of metastases were derived from early disseminated cancer cells. Karyotypic and phenotypic analysis of human disseminated cancer cells and primary tumours corroborated the relevance of these findings for human metastatic dissemination.
with low to moderate HER2 expression in early lesions and wildtype mammary tissue (Extended Data Fig. 1f ). We therefore quantified HER2 and PGR protein expression in mammary cells displaying normal, hyperplastic or advanced tumour morphology. The number and staining intensity of HER2 + cells steadily increased with advancing tumour morphology, in which early lesions had intermediate cell numbers and HER2 expression levels. PGR staining intensity was constant, but the number of PGR + cells declined from approximately 40% in normal glands to 0% in primary tumours (Fig. 1d ).
The early lesion signature could be activated in 4T1, an MMTV-HER2negative mouse tumorigenic cell line (Extended Data Fig. 1g ) that displays weak endogenous HER2 expression (Extended Data Fig. 1h ). Furthermore, HER2negative mouse tumour cells (67NR and MM3MG cells) did not express the early lesion signature (Extended Data Fig. 1g ), but progesterone treatment or transduction of the B isoform of PGR (Pgr-B) induced upregulation of HER2 in 4T1 or MM3MG cells, respectively (Extended Data Fig. 1hi ). Collectively, these results suggested that the genetic program of early lesions depends on the combined activation of progesterone and HER2 pathways.
Progesterone induces migration of early lesion cells
Because progesterone mediates branching 14 in mammary gland devel opment, we investigated the role of the progesteroneinduced early lesion signature in cancer cell migration. We found that the mRNA levels of the progesteroneinduced paracrine signals (PIPS) Rankl (also known as Tnfsf11) and Wnt4 were upregulated in early lesion samples (Extended Data Fig. 2a ). Treatment of earlylesionderived cells with PIPS mimicked the effect of progesterone (Extended Data Fig. 2b ), suggesting that early lesions exploit the mechanisms of mammary branching for metastasis. Consistent with this, PGR + cells were enriched in distal ducts of normal mammary glands (advancing the branching tree away from the nipple during developmental fat pad invasion) compared to proximal ducts closer to the origin (more differentiated ducts; Extended Data Fig. 2c, d) .
Furthermore, progesterone and PIPS induced migration of mam mary cells from earlylesionderived samples (freshly prepared or earlylesionderived mammospheres) and suppressed migration in cells from primary tumours ( Fig. 2a and Extended Data Fig. 2e , f).
PIPS also activate mammary stem cells during mammary gland development 17 , prompting us to analyse mammosphere formation 18 . Consistent with previous reports on HER2stimulated stemness 19, 20 BALBNeuTderived samples generated significantly higher numbers of spheres than controls ( Fig. 2b) . Notably, normal mammary cells derived from young (4-9weekold) mice generated more spheres than cells derived from older mice ( Fig. 2b ). Furthermore, earlylesionderived cells gene rated higher sphere numbers in response to progesterone and PIPS than primary tumour samples (P ≤ 0.01; Fig. 2c ). Neutralizing antibodies against RANKL and a WNT inhibitor abrogated the effect of progesterone on early lesion cell migration and sphere formation ( Fig. 2d ).
Migrating early lesion cells (that is, those arriving on the other side of the transwell membrane) formed increased sphere numbers in response to progesterone ( Fig. 2e and Extended Data Fig. 2g ). Oestrogen also induced migration and sphere formation, however, the progesterone inhibitor RU486 inhibited this promigratory and prosphereforming effect (Extended Data Fig. 2h ), possibly because oestrogen acts via transcrip tional induction of Pgr 21 . Together, these results suggested that moderate HER2 expression with progesterone or PIPS availability promote sphereformation and migratory responses in mammary epithelial cells.
HER2 expression levels determine cellular responses
We next performed a series of mechanistic in vitro experiments using mouse mammary epithelial MM3MG cells (oestrogen receptor (ERα ) negative but expressing low levels of PGR and HER2). MM3MG cells transduced with Pgr-B or Her2 were subjected to sphereformation and migration assays (Extended Data Fig. 3 ). PIPSresponsive cells (in both migration and sphereformation assays) were HER2 low /PGR − , whereas PGR + cells themselves were not migrating and HER2 high cells were similar to nonmigrating primary tumour cells and showed enhanced proliferation.
Cell density regulates HER2 and PGR expression
Notably, individual primarytumourderived cells reexpressed Pgr mRNA and protein when cultured at low cellular densities (Extended Data Fig. 4a, b ). We therefore plated the BALBNeuT primarytumour derived TUBO cell line at different cell densities and found PGR article reSearcH expression in 10 ± 5% (mean ± s.d.) of cells grown at low density, but undetectable PGR expression in cells grown at high density ( Fig. 3a) . Several experiments suggested that there was a soluble factor with PGRsuppressing activity in the vesicular fraction of cell culture supernatants, and that this activity was conserved between mouse and human (Extended Data Fig. 4b-e ). To identify this activity, we analysed the microRNA (miRNA) profiles of supernatants with and without exosomes from TUBO cells and the HER2overexpressing cell line MM3MG-Her2. miRNA sequencing (Supplementary Data 2) and bioinformatic prediction of Pgr regulators (Extended Data Fig. 4f Moreover, we observed density regulation of migration and sphere formation in 10 out of 10 human breast cancer cell lines tested (7 out of 10 by PIPS and 3 out of 10 by progesterone induction; Fig. 3e and Extended Data Fig. 5e ).
To assess the contribution of cell density in vivo, we compared meta stasis formation of transplanted primary tumour pieces (very high cell density) with primary tumourspheres (50 spheres injected in 40 μ l Matrigel, that is, very low density). After primary tumour formation, we performed curative surgery and evaluated metastasis formation. No difference was found in the percentage of mice with metastases (8 out of 19 for tumour pieces compared with 6 out of 16 for spheres), however, animals transplanted with primary tumourspheres had a higher number of metastases (P ≤ 0.05; Fig. 3f ). In summary, we obtained support for a model of metastatic dissemination regulated by cell density, HER2 expression and progesterone signalling ( Fig. 3g ).
PGR signalling regulates dissemination in vivo
To validate these findings, we analysed physiological conditions of reduced (higher age; Extended Data Figs 1f, 2a, 6a, b) and increased (pregnancy) PGR signalling. We transplanted spheres gene rated from early lesions and primary tumour samples into young (4 weeks of age; PGRrich) and old (40 weeks of age; PGRreduced) wild type recipients. All mice were killed when the first mice developed tumours of 5-10 mm diameter (8 weeks later). Most mice transplanted with primary tumours had palpable tumours, but none of the mice transplanted with early lesions (Fig. 4a ), although these nevertheless harboured microscopic early lesions and/or ductal carcinoma in situ (DCIS) (Extended Data Fig. 6c, d) . Notably, transplantation of spheres from early lesions increased the number of animals containing DCCs, and resulted in higher numbers of DCCs in bone marrow compared to transplantation of primary tumourspheres (Fig. 4b, c ).
There was suppressed dissemination and stimulated tumour for mation from primary tumourspheres in the PGRrich microenviron ment of young mammary glands ( Fig. 4d and Extended Data Fig. 6e ) as expected. Dissemination from early lesions was not reduced in old recipients ( Fig. 4d ). However, the transplanted early lesions generated a PGRrich microenvironment in old recipients (Extended Data Fig. 6d ), consistent with the observation that cells from early lesions, but not from primary tumours, could generate PGRpositive cells in 3D culture (Extended Data Fig. 6f , g). Cotransplantation of BALB NeuT primary tumourspheres with MM3MG-PgrB into 40weekold mice resulted in reduction of dissemination and stimulation of tumour formation (Extended Data Fig. 6h , i).
Because progesterone levels are physiologically increased 10 to 20fold during pregnancy, we mated female transgenic mice at the age when early lesions (week 7) and early tumour formation (week 15) occurred. Mice were killed at term, and those mated at the early lesion age displayed higher numbers of DCCs (Extended Data Fig. 6j ); whereas those mated at week 15 formed large tumours within 3 weeks, faster than unmated controls (Extended Data Fig. 6k ).
To assess metastasis from early lesions and primary tumour lesions, we transplanted pieces of mammary glands (gland model) of 4-5week old transgenic mice or from primary tumours (primary tumour model) into the cleared mammary fat pad of 4weekold wildtype recipients (Extended Data Fig. 6l , m). Tumour growth to 5-10 mm was fast in animals transplanted with primary tumour pieces (indicating their high viability) and took longer in animals in the gland model ( Fig. 4e ). After surgical removal of primary tumours (Extended Data Fig. 6l , m), more mice displayed metastasis in the gland model ( Fig. 4f ; P < 0.0001), Week 40
Week 4
Week article reSearcH although numbers of metastatic foci were similar in both cases (Extended Data Fig. 6n ). Since the slower growth of early lesions until surgery might have extended the available time for metastasis forma tion, assuming dissemination occurred early, we restricted our analysis to mice with similar kinetics of primary tumour growth (red box in Fig. 4e and Extended Data Fig. 6o ). Again, more mice developed lung metastases in the gland model ( Fig. 4g ), although in the analysis of this subgroup, followup time after tumour surgery was significantly longer for mice from the primary tumour model (Extended Data Fig. 6p ). The number of metastases was similar (Extended Data Fig. 6q ). Together, the in vivo results are in line with in vitro findings that PIPS induce migration and stemness of early lesion cells and proliferation of advanced primary tumour cells.
We used the gland model to determine which metastases were derived from early rather than late DCCs and performed phylogenetic analyses of 28 primary tumours with 1 or more lung metastases in the same mouse. Phylogenetic trees were generated from copy number alterations, since BALBNeuT tumours rarely display point mutations, similar to human breast cancer 22 . Total numbers of copynumber alterations were indistinguishable between primary tumours and metastases (Extended Data Fig. 7a ) and no individual change was significantly associated with primary tumour or metastasis origin (Extended Data Fig. 7b ). This suggested that aberrations shared between primary tumours and metastases were acquired earlier, indicating the time of genetic divergence ( Fig. 4h, i) . In all cases, we observed branching evolution with none or one (single metastasis) or several (multiple metastases; Fig. 4i and Extended Data Figs 7-9) ancestors. To assign derivation of primary tumours and metastases as from early or late DCCs, we assessed the propor tion of primary tumour alterations that were already present in the last common ancestor. In linear progression, this value would be 1 (the primary tumour had acquired all mutations before the metastatic precursor left the site). Here, we used the very conservative threshold of ≥ 0.5 for late dissemination. Notably, we found that for 35 out of 44 individual primary tumour-metastasis pairs (79.5%), lung metastases were derived from eDCCs that disseminated before the primary tumour had acquired 50% of its alterations ( Fig. 4j ).
HER2 and PGR cooperation in human metastasis
The mechanisms of breast cancer dissemination described above can not be studied directly in patients, as the event occurs before diagnosis. We therefore checked whether human breast cancers could also seed relatively fewer bonemarrow DCCs (detected by cytokeratin staining 23 ) with growing primary tumour size, as seen in the BALBNeuT model (Extended Data Fig. 1a ). Indeed, the percentage of DCCpositive patients or DCC numbers in bone marrow of 2,239 patients with breast cancer did not increase with tumour diameter (Fig. 5a ). We then investigated whether DCC numbers were associated with HER2 and PGR expression and categorized primary tumours according to their expression levels of PGR and HER2 ( Supplementary Table 4 ). Notably, in breast cancers with a high PGR score, genetic activation of HER2 increased the dissemination rate (P ≤ 0.05; Fig. 5b ), akin to early lesions in the BALBNeuT model. This subgroup of patients (HER2 amp /PGR high ) comprised 3.7% of all patients (85 out of 2,239) or 24.6% of patients with HER2amplified tumours (85 out of 345). HER2 amp /PGR high (Supplementary Table 5 ) primary tumours con tained HER2 and PGR single and doublepositive and doublenegative cells (Extended Data Fig. 10a ). Areas of high cell density lacked PGR expression and invasive regions of lower density contained strongly doublepositive cells ( Fig. 5c ), suggesting densitymediated PGR regu lation within the same samples. We therefore analysed the expression of PGRregulatory miRNAs identified in the BALBNeuT mouse model (Supplementary Table 6 ). HER2 amp /PGR high tumours displayed lower levels of PGRdownregulating miRNAs compared to HER2 amp /PGR neg tumours (Fig. 5d ), similar to the human HER2 high /PGR high cell lines BT474 and T47D (Extended Data Fig. 5a, b ). PGRnegative, highdensity regions from HER2 amp /PGR high samples (Fig. 5c ) displayed strong PGRregulating miRNA overexpression (Extended Data Fig. 10b ). DCCs from patients with breast cancer without metastasis (stage M0; n = 94 cells; Supplementary Table 7 ) and with metastasis (stage M1; n = 91 cells) were compared to bulk primary breast cancers (n = 1,637) from a large database (Progenetix database; http://www. progenetix.net). Comparative genome hybridization profiles of pri mary tumours were very similar to those of single DCCs isolated from M1stage patients ( Fig. 5e ). By contrast, single DCCs from M0stage patients, although these displayed clearly aberrant profiles, lacked the chromosomal gains and losses characteristic of primary tumours, such as 8p loss or 8q gain (Fig. 5e ). Thus we can conclude that: (i) DCCs often disseminate before the acquisition of typical breast cancer copynumber alterations; (ii) tumour cells displaying the typical karyo type of established tumours are rarely found at M0stage of disease in the bone marrow; (iii) DCCs displaying M1like genomes must replace DCCs with M0like genomes to generate metastatic disease, even when the primary tumour was surgically removed.
Finally, we tested whether human DCCs (n = 26) isolated from the bone marrow of 18 patients with luminal and 1 patient with triple negative breast cancer (Supplementary Table 8 ) lacked PGR expression as predicted by the BALBNeuT model (Extended Data Fig. 3o ). We identified and profiled DCCs by combined genome and transcriptome analyses of single cells 24 . None of the 26 DCCs displaying genomic aberrations expressed PGR (Fig. 5f ). Notably, the only DCC expressing HER2 transcripts originated from one of two patients diagnosed with hormone receptor positive DCIS only.
Discussion
This work provides evidence that mouse and human mammary cancer cells migrate and disseminate from morphologically very early lesions. The mechanism, which is shut down as primary tumours grow and overt lesions develop, consists of three major components: cell density, PGR signalling and HER2 signalling. While the specific molecu lar details are more likely to be tissue dependent than universal, our proposed mechanism may provide a general framework for the under standing of metastasis with cancer cells undergoing a switch from a dissemination to proliferation mode ( Fig. 3g ).
Our findings challenge the concept that latedisseminating (that is, shortly before surgery), fully mature cancer cells necessarily have a higher ability to form metastases 13 . Indeed, our genetic analyses showed that 80% of metastases in BALBNeuT mice were derived from eDCCs. The genomic profiles of human DCCs isolated intraoperatively months to years before metastasis represented early cancer cells, not the pre dominant primary tumour clones, indicating that eDCCs have yet to acquire critical alterations such as gains on chromosome 8q to form metastases. The time to acquire such changes may largely account for the long latency periods and late relapses, which are becoming clinically more and more relevant 25 . Therefore, parallel progression 7 seems to be typical rather than exceptional. This is supported by a recent sequencing study, in which not a single case of linear progression from primary tumour to metastasis was found 26 .
Our data indicate that breast cancer hijacks a developmental pro gram, in which progesterone and its paracrine signals regulate mam mary epithelial branching, fat pad invasion 14, 27, 28 and mammary stemcell expansion 14, 17, 18, [29] [30] [31] during development and pregnancy, for dissemination, independently of breast cancer subtype. Relevance to human disease is highlighted by a careful analysis of mortality from DCIS, hitherto defined as preinvasive lesion 32 . Of the 3% of DCIS fatalities, more than 50% die of metastasis without local relapse, indi cating lethal dissemination before surgery of the preinvasive lesion 32 . Evidently, dissemination will also occur early if the tumour is not diagnosed as DCIS but later as invasive cancer. Moreover, death from DCIS increased significantly to 8% for young women 32 , possibly because in young women the epithelial compartment and the micro environment have high PGR expression.
The gradual generation of a HER2 high /PGR − phenotype may explain why early lesions of the BALBNeuT model, but not advanced tumours, were found to represent human luminal tumours 33 . The BALBNeuT model apparently represents a mixed luminal and HER2 phenotype and models several breast cancer subtypes. Cell density, progesterone, PIPS and HER2 signalling regulated dissemination and sphere formation in breast cancer cell lines of all subtypes similar to the BALBNeuT model. Notably, HER2positive circulating tumour cells were detected in DCIS and lobular carcinoma in situ or patients with M0stage breast cancer irrespective of the HER2 status of the primary tumour 34 .
High cell density and HER2 expression were responsible for the proliferative switch of mammary epithelial cells. Oncogenic muta tions characterize benign tumours that do not metastasize [35] [36] [37] ; indeed, strong activation of oncogenic pathways represses metastasis while increasing proliferation 38, 39 . However, our experiments do not exclude the possibility that metastases form from advanced tumours because the early lesion dissemination program may become reactivated in areas of low cell density.
Our findings have implications for the understanding of metastasis and development of therapies: systemically spread cancer cells probably comprise cells derived from different stages of primary tumour evolu tion, including the earliest. Since DCCs from early and later stages have metastatic potential, therapies targeting the seed of metastasis need to address this heterogeneity. Briefly, gland or tumour areas were calculated from 270 mammary glands or tumours of 27 mice assuming the shape of an ellipse or circle for each tumour. The tumour area of mammary glands without palpable (that is, not measurable by a caliper) tumours was set to 0.1 mm 2 (that is, assuming a diameter of 350 μ m of a total, circular hyperplastic lesion within a mammary gland) for lesions from 4-9weekold mice and 0.4 mm 2 for 11weekold mice. The adjustment for 11weekold mice was based on a microscopic evaluation showing an about 4fold increase in hyperplastic lesions. Dissemination to the bone marrow was determined by the number of cytokeratinpositive cells per 10 6 bonemarrow cells (Extended Data Fig. 1a ).
Mouse bone marrow preparation and staining for DCCs. Bone marrow was
collected from femurs and tibiae. The bone marrow was rinsed with a 26G needle with 1 ml of PBS. After density gradient centrifugation, 5 × 10 5 interphase cells were put on adhesion slides (Menzel). At least 10 6 cells per mouse were stained to detect positive cells. Blocking solution (5% rabbit serum in 1× TBS (50 mM Tris base, 150 mM Nacl, pH 7.4)) was added to the slides to rehydrate the cells and to block unspecific binding of antibodies to the cells. After 20 min the blocking solu tion was discarded and primary antibody against cytokeratins 8 and 18 (CK8/18; all antibodies and working concentrations are in Supplementary Table 9 ) or guinea pig serum (the CK antibody originated from guinea pig) as control, was added and slides were incubated for 60 min. The primary antibody was discarded and the slides were washed 3× for 3 min in 1× TBS. The slides were incubated with the secondary antibody for 25 min, and then washed 3× for 3 min in 1× TBS followed by incubation with the ABC complex (Vector Laboratory) for 25 min. Finally, the development system of the BCIP/NBT (AP Conjugate Substrate Kit, BioRad Laboratories GmbH, 1706432; Levamisol hydrochloride, SigmaAldrich GmbH, L9756) for alkaline phosphatase enzymatic substrate was added for 10 min. The slides were washed 3× for 3 min and screened for CK8/18positive cells. The posi tive cells were typically violettoblack in colour. TUBO, a tumour cell line derived from a mouse primary mammary tumour of BALBNeuT and known to express CK8/18, was used as a positive control. Laser microdissection and microarray analysis. Laser microdissection (PALM MicroBeam from Carl Zeiss MicroImaging GmbH) was performed to dissect meta static lesions from lungs, primary tumours and epithelial layers of mammary glands of BALBNeuT mice at the time point of early lesions (7-9weekold mice; examples are shown in Extended Data Fig. 1b) , and BALB/c mice at different ages (description of samples is given in Supplementary Table 1 ). Small pieces adding up to 100,000 μ m 2 for each sample were catapulted into a cap with 10 μ l para magnetic, biotinylated, oligodTpeptide, nucleicacid, bead suspension and lysis buffer (Active Motif, 29011). Extraction of mRNA and microarray experiments were performed as described previously 40 . Heatmaps in Fig. 1a were generated using Euclidean distance and complete linkage agglomerative clustering on row (gene)wise standardized expression data (zero mean, unit standard deviation).
Cell lines, cell culture and cell stimulation. Breast cancer cell lines (4T1, 66cl4, and 67NR) were provided by F. Miller. These cell lines were derived from a single mammary tumour that arose spontaneously in a wildtype BALB/cfC3H mouse. The MM3MG mouse mammary epithelial cell line derived from a BALB/c back ground was purchased from ATCC (ATCC CRL6376). The TUBO cell line is a cloned cell line established in vitro from a lobular carcinoma that arose spon taneously in a BALBNeuT mouse (gift from G. Forni). All mouse and stably transduced cell lines were grown in DMEM medium (PanBiotech, P0403500) supplemented with 10% (20% for TUBO cell line) FCS (PanBiotech: P303702), 2 mM lglutamine (PanBiotech, P0480100), 10 U ml −1 penicillin/streptomy cin (PanBiotech, P0607050). All human cell lines were purchased from ATCC and each cell line was maintained in medium recommended by ATCC. The origin of the cell lines was confirmed by short tandem repeat (STR) analysis (CellID, Promega). All cells were incubated at 37 °C with 5% CO 2 
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For the combined migration/sphere formation assay, cells were placed on a layer of 30% Matrigel in the upper chamber and the lower chamber was coated with polyHEMA. The mammosphere medium used is described above. After 72 h, inserts were removed, fixed and stained with trypan blue for single cell migration analysis. 600 μ l fresh sphere medium was added to the lower chamber and cells were incubated for 11 days when spheres were counted ( Fig. 2e and Extended Data Fig. 2g ). Proliferation assay. Singlecell suspensions were cultured in 96well plates (Corning Inc) and proliferation was evaluated by a XTTcolorimetric assay kit (Roche, 11465015001) based on the manufacturer's instructions. Seeding con centration of cells was 3,000 cells per well. The experiment was performed with 6 technical replicates. The medium was supplemented with the tested factors or hormones and vehicle (see corresponding experiments) and was changed every second day. Immunohistochemistry. For PGR and HER2 immunohistochemistry of tissue sections, we used 5μ m sections of paraffin blocks placed onto polyllysinecoated slides. Samples were dewaxed by two 5min washes in xylene and rehydrated with graded alcohol by 5min washes and a final wash in water. A standard Tris-EDTA buffer and pressurecooking was used for antigen retrieval and then sections were blocked in 0.3% H 2 O 2 in TBS and 10% normal goat serum. Sections were incubated for 1 h with primary antibodies and, after washing, secondary antibodies (Vector laboratory, PK4001 or PK5000) were added based on the manufacturer's recom mended dilution (see Supplementary Table 9 ). After washing with PBS, sections were stained using the ABC detection system (Vector Laboratory) according to the manufacturer's instruction. Visualization was performed with chromogen reagent (Dako, 10046560) according to manufacturer's instructions. Immunofluorescence staining. For staining of cells from monolayer cell cul tures, cells were seeded onto 24well culture plates at an appropriate density. After 72 h of incubation, cells were washed with PBS and fixed with 4% PFA for 10 min. Then, cells were permeabilized with 0.2% Triton X100 followed by washing steps and blocking with 1% BSA in PBS at 37 °C and incubated with primary antibody (see Supplementary Table 9 ) for 1 h at room temperature. Cells were then washed 3× with PBS and incubated with labelled secondary antibody (Jackson ImmunoResearch Laboratory Inc) for 1 h at room temperature. For nuclear counterstaining, cells were incubated for 10 min with 0.5 μ g ml −1 DAPI (SigmaAldrich). For the staining of spheres in differentiation experiments, mam mospheres were picked and transferred to a 24well cellculture plate and incubated for 8 h in sphere medium in order to fix them to the surface. The subsequent staining protocol was as for monolayer cell culture staining. For staining of cells attached to the inserts from migration experiments, inserts were used directly after migration (see migration assay), for the blocking step and immunofluorescence staining, the monolayer cell culture staining procedure was applied. Images were captured on an AxioVert 200M microscopy (Carl Zeiss Microscopy). Quantification of HER2 and PGR staining in tissue sections by TissueFAX cytometry. Tissue sections were stained with an automated staining machine (Ventana, BenchMark ULTRA). Tissue sections used for analysis were stained within the same run. Images of stained tissue sections were scanned with the TissueFAXSiplus imaging system (TissueGnostics, Vienna, Austria; acquisition software: TissueFAXS v3.5.129) equipped with a digital Pixelink colour camera (PCO AG). Images for the analysis of HER2 and PGR staining were analysed with HistoQuest software v3.5.3.0185 (TissueGnostics). Using the HistoQuest software, two markers were created: haematoxylin as master marker (nucleus) and HER2 or PGR as nonmaster marker. To achieve optimal cell detection, the following parameters were adjusted: (i) nuclei size; (ii) discrimination by area; (iii) discrimination by grey and (iv) background threshold. For the evaluation of the HER2 staining intensity of cells or the percentage of PGRexpressing cells, histo grams were created, allowing the visualization of corresponding cells in the source region of interest using the realtime backgating feature. The cutoff discriminated between false events and specific signals according to cell size and intensity of staining. For HER2 staining, 38,675 primary tumour cells (6 regions, 1.99 mm 2 ), 28,850 cells from hyperplastic regions (25 regions, 1.55 mm 2 ) and 14,938 cells from nontransformed ducts (30 regions, 0.93 mm 2 ) were analysed. For PGR, 12,269 cells of early lesions (hyperplasia, 7 weeks, 11 regions, 0.5 mm 2 ), 12,702 cells of nontransformed (normal duct, 7 weeks, 56 regions, 0.7 mm 2 ) and 25,357 primary tumour cells (9 regions, 1.3 mm 2 ) were analysed (Fig. 1d) . Quantitative PCR. All mRNA extractions were performed using the RNeasy kit (Qiagen, 74104) according to the manufacturer's instructions. For miRNA extrac tion, the miScript II RT Kit (Qiagen, 217004) was used. cDNA was generated using a reverse transcriptase kit (Qiagen, 205311 for total RNA and 218161 for miRNA). Finally, 25 ng of cDNA was used for qPCR. qPCR was performed using a LightCycler instrument (Roche) and Fast Start Master SYBR Green Kits (Roche). Data analysis was done using the RelQuant software (Roche) with a reference gene and a calibrator (reference) sample in every run. Mouse reference cDNA served as a positive control. Samples with unspecific products in the melting curve analysis were discarded from further analysis. Expression levels are given relative to Actb (β actin) for gene expression analyses and Rnu6 for miRNA anal yses (primer sequences are provided in Supplementary Table 10 ). All primers for mRNA analyses were synthesized by Eurofins MWG Operon, and by Qiagen for miRNA analyses.
For comparison of miRNA levels in highdensity and lowdensity regions (Extended Data Fig. 10b ) of formalinfixed paraffinembedded samples, regions were punched out using a 1.5mm puncher (PFM medical; 48115). Samples were incubated for 10 min at 70 °C followed by xylene-ethanol deparaffinization and overnight proteinase K (0.5 μ g μ l −1 , Roche 03115828001) digestion. Then miRNA extraction was performed using the miRNeasy kit. For comparison of miR30a5p and miR95p between HER high /PGR high human mammary carci nomas and HER2 high /PGR − carcinomas, miRNAs were extracted from freshly frozen samples using the miRNeasy kit. Expression of miR95p and miR30a5p was normalized to HER2 − /PGR high breast cancers (see Supplementary Table 6 for details on patients). Lenti-and gamma retroviral transduction. PGR expression was carried out with a lentiviral construct encoding human PGR-B (GeneCopeia, Z5911). Lentiviral packaging was conducted as previously described 41 . Helper vectors were pSPAX2 and pMD2.G (Addgene). Selection was performed using 10 μ g ml −1 of puromycin (SigmaAldrich, P8833). For Her2 expression pLXSN-NNeu (rat wildtype Neu/Her2) was used (obtained from L. Petti) 42 . Retroviral delivery of transgenes was performed as described previously 43 . Helper vectors were pCMV-VSVG and pUMVC3 obtained from Addgene. Selection was performed using 1,000 μ g ml −1 of G418 (SigmaAldrich, G9516 ). MM3MG cells were transduced with lentiviruses and/or retroviral vectors and cell colonies were selected using antibiotics. Positively transduced clones were expanded and screened for PGR and/or HER2 levels by western blot analysis and qPCR. Western blot analysis. Cell lysates were prepared using RIPA buffer (Sigma Aldrich, R0278) and were analysed with the BCA protein assay kit (Thermo Scientific, 23227) to measure and their protein concentration was equalized. Quantified protein lysates were resolved on 6.5% SDS-PAGE gels, and transferred onto a polyvinylidene difluoride membrane (Millipore), and immunoblotted with the primary antibodies overnight followed by incubation with the horseradish peroxidaseconjugated secondary antibodies. The blots were visualized using a substrate kit (GE Healthcare, RPN2109) and bands were visualized by Imagequant LAS 4000 (GE Healthcare). The full blot images are shown in Supplementary Fig. 1 . Exosome isolation, miRNA analyses and sequencing. To prepare conditioned medium, TUBO cells were seeded at a density of 3 × 10 4 cells per cm 2 . After 4 days, medium was collected, centrifuged and filtered and used as conditioned medium. For exosome isolation we used an ultracentrifugation method as previ ously described 44 . Exosome pellets were resuspended in fresh medium and used for T47D cell line treatment. PGR expression was checked at different time points (4, 8, 24 , and 48 h). For miRNA sequencing we used 4 × 10 6 cells and exosomes were isolated from confluent medium from TUBO cells. The miRNA cloning and sequencing was done as described previously 45 . All pooled samples were sequenced on a MiSeq system (Illumina) in a singleend run with 80 cycles using the MiSeq reagent kit v3. Data analysis was performed using inhouse written scripts. Sequences were mapped-without any mismatches allowed-against mouse miR NAs listed in the miRBase v20 (June 2013; http://www.mirbase.org). The minimum length of reads was set to 18 nucleotides. Annotated miRNAreads were normalized as RPM values according to the total number of mapped reads in the respective library. Mimic miRNAs were ordered from Eurofins MWG Operon Company and all sequences are listed in Supplementary Table 11 . For miRNA transfection we used reverse transfection protocols according to instructions for RNAiMAX (Life Technology, 13778030) and with a 50 nM concentration of miRNA. Mouse genome comparative genome hybridization microarrays. DNA samples were extracted from freshly frozen samples using the DNeasy Blood & Tissue Kit (Qiagen, 69504). Genomic DNA labelling was done using the Agilent SureTag DNA Labelling Kit (Agilent, 51903400). Array CGH was performed on oligo nucleotidebased SurePrint G3 Mouse CGH Microarray Kit, 4x180K (design code: 027411) according to the protocol provided by the manufacturer (Agilent Oligonucleotide ArrayBased CGH for Genomic DNA Analysis, v.7.2, July 2012). Phylogeny of primary tumours and metastases. Ancestral relations among matched samples of primary tumour and metastases were inferred using array CGH pro files. The array comparative genomic hybridization dataset consisted of 28 primary tumour samples with 1-3 corresponding metastasis samples (18 primary tumours with 1 metastasis; 4 with 2 metastases and 6 with 3 metastases).
Positions of the probes on the array were mapped to the current mouse refer ence genome (mm10) using the liftOver tool 46 . No background correction was applied to the data 47 . The data were first normalized within arrays using Loess 48 . Then, log ratios were corrected for spatial artefacts using a median filter with an 11 × 11 block of probes 49 and a between array scale normalization was applied 50 . Duplicate probes (having the same genomic position) were summarized by their median log ratio. The R package limma 51 (v.3.28.1) was used for normalization within arrays and between arrays (with default parameters). In a final step, wavy patterns were removed from the data using an approach similar to ref. 52 , but with modifications to account for broad copynumber alterations. For every sample and chromosome, correction was carried out as follows. Because the maximum number of broad copynumber alterations on any chromosome observed in the data was two, a piecewise constant function with two pieces was fitted to the log ratios to estimate these broad alterations. Each piece was required to be longer than 5% of the chromosome length to avoid spurious small pieces. The wavy pattern was estimated by fitting a Loess curve with a window size of 100 probes to the residuals of the piecewise constant function fit. To avoid smoothing true focal alterations, the weight of probes with an absolute log ratio deviation greater than 0.5 from the piecewise constant function were set to 0 for the Loess fit. The estimated wavy pattern was then subtracted from the log ratios resulting in corrected values.
After normalization the log ratios were segmented using Circular Binary Segmentation as implemented in the R package DNAcopy 53 (v.1.46.0). The default parameters were used except for α , which was set to 0.001. Segments with a length of 5 or less probes were merged with the closest adjacent segment. For every sam ple, states with means closer than 0.05 were merged iteratively beginning with the two states with closest means. When two states were merged the new mean was given by the mean of the two old state means weighted by the number of probes in every state. After state merging, the remaining segment means were adjusted to have a median of 0. These segmented copy number profiles were then decon structed into underlying copy number events using Ziggurat Deconstruction 54 . All these steps where performed using R (v.3.3.0).
Aberration events as defined by left and right change points, and aberration type were pooled across the matched samples of a single mouse to form a mousespecific base set of aberration prototypes. For this, amplifications and deletions that were similar by more than 80% as measured by their Jaccardindex regarding probe support were merged into single prototypes using Jaccarddistancebased com plete linkage clustering and union of supports. Individual primary tumour and metastases samples were then encoded according to presence (absence) of the prototypic aberrations, whereby the present prototype was called by the minimum Jaccarddistance. The resulting feature vectors were then used for phylogenetic tree inference. Phylogenetic trees were generated by assuming ideal (that is, error free) data and inferring plausible common ancestors (intermediates) of aberration profiles by extracting shared features of an increasing number of samples, that is, evaluating common aberration events in sample pairs, triplets, quads, and so on, and organizing these ancestors according to hierarchical levels. Subsequently, admissible edges were constructed topdown between vertices allowing for two relosses of acquired gains and no regains of any losses (this condition was also ensured globally for each path). Then all simple paths from the normal cell to the samples were generated using the Igraph Rpackage (v.1.0.0), combined into a directed acyclic graph and filtered for the fewest genomic changes along the graph and lowest number of intermediates (maximum parsimony). This resulted in one unique phylogenetic tree for each mouse. Detection of human DCCs. For CGH analysis of single DCCs, bonemarrow sampling of patients with M1 stage cancer was performed within the study pro tocol of the GEBDIS study at the Central Hospital in Augsburg after informed, written consent of patients was obtained. The ethics committees of the University of Munich (ethics vote number 007/02) and Regensburg (ethics vote number 07079) approved bone marrow sampling (including patients with M0stage cancer) and genomic analysis of isolated cells. For all patients informed, written consent was obtained. For bonemarrow sampling and analysis for cytokeratinpositive cells of patients from Tübingen (approval by the ethics committee of Tübingen University, reference number 560/2012R) all specimens were obtained after written, informed consent. Bonemarrow sample preparation, slide preparation, cytokeratin staining and cell isolation was performed as previously described 5 .
Whole genome amplification and single cell comparative genomic hybridization.
Whole genome amplification was performed as previously described 5, 55 . The method has become commercially available as a kit (Ampli1, Silicon Biosystems). A histogram of copynumber alterations (Fig. 5e ) was generated for human pri mary breast cancers (n = 1,637) derived from the Progenetix database (http://www. progenetix.net) and DCCs isolated from bone marrow of breast cancer patients without (M0, n = 94; see Supplementary Table 7 for clinical details of patients) and with metastasis (M1, n = 91). Analysis of patients with breast cancer for association of DCC and primary tumour receptor expression. We analysed data of 2,239 patients from the Department of Oncology and Obstetrics, University of Tübingen. DCC status was assessed according to the consensus protocol 23 , using the anticytokeratin antibody A45B/B3 and by evaluating 2 × 10 6 bonemarrow cells. PGR expression of primary tumours was categorized into PGR staining scores 0-1 for absent expression; 2-8 for intermediate expression and 9-12 for high expression. HER2 status of primary tumours was categorized into the staining score 0 for absence of HER2 staining (IHC negative); score 1 and score 2 without HER2 amplification (IHC positive) and score 2 with HER2 amplification and 3 (which is known to be caused by HER2 amplification; FISH positive). Bioinformatics and statistical analysis. Statistical analyses and estimation of variation within each group of data were performed using GraphPad Prism v.6 and R v.3.3.1. For in vivo DCC experiments of primary tumour compared to early lesion spheres, sample size was estimated using G* Power (v3). No statistical methods were used to predetermine sample size for other experiments. For each experiment, mouse numbers are given in the figures or the text. All in vitro and primary culture experiments were performed at least in triplicate and Student's ttest was used for comparisons. For all other experiments we applied the D' AgostinoPearson omnibus normality test. When sample size was sufficiently large (n ≥ 8) and were not distributed normally according to the D' AgostinoPearson test (P ≤ 0.05) we applied the Mann-Whitney Utest. For gene signature evaluation in Figs 1c, 3d and Extended Data Fig. 1e , g, gene wise ttest P values were combined using Stouffer's method. A linear regression test (Ftest for slopes) was used to compare proliferation curves and tumour growth. For comparing numbers between different groups we applied Fisher's exact test or if the sample numbers were at least 5 in each condition the χ 2 test. In Fig. 1d 
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Extended Data Figure 2 | Progesterone regulates migration and is linked to branching morphogenesis. a, qPCR analysis of Pgr, Rank (also known as Tnfrsf11a), Rankl and Wnt4 in normal and transgenic mouse mammary tissue or tumours. Note the increased expression of Pgr, Wnt4 and Rankl in early lesions compared to primary tumours. Only Rank (the Rankl receptor) is strongly expressed in primary tumours. b, Primary cultures of early lesions treated with progesterone, WNT4, and RANKL. WNT4 and RANKL treatment induce the early lesion signature and act synergistically. c, d, PGR (green) staining at 5 and 12 weeks of age (FVB wildtype mice). Scale bars, 100 μ m. The percentage of PGR + cells per duct was quantified (n = 2 mice per age group) in the distal and proximal portions of the gland (relative to the origin). PGRexpressing cells were more abundant in distal ducts (number of analysed ducts per group is displayed above each column). LN, lymph node.e, f, Photomicrograph of migration assay (e) and quantification of migrating cells (f) derived from fresh tissue (e, left) or dissociated spheres derived from primary tumours or early lesions (e, right; f, quantification). Progesterone, WNT4 and RANKL induce migration of earlylesionderived but not primary tumourderived cells (see also Fig. 2a ). g, Scheme of combined migration and sphere assay. The lower chamber is filled with serumfree sphere medium and the bottom is covered with polyHEMA to prevent adhesion and enable sphere formation. After 72 h migration, the insert is removed and the lower chamber is analysed (after 11 days) for mammosphere formation (see Methods). h, Effect of oestrogen and progesterone on migration and sphere formation of mammary cells derived from early lesions. Cells were exposed to 10 nM oestrogen or progesterone or 10 nM oestrogen + 10 nM progesterone inhibitor (RU486). * P ≤ 0.05; * * P ≤ 0.01; * * * P ≤ 0.001; * * * * P ≤ 0.0001 (Student's ttest); Data are mean ± s.e.m. article reSearcH Extended Data Figure 3 | HER2 expression levels regulate migration and proliferation. a, Parental MM3MG cells, a cell line derived from mammary epithelial cells of wildtype BALB/c mice, do not express ERα but express low levels of HER2 and PGRB compared to 4T1 and TUBO cells (TUBO cells were grown at low density; see Fig. 3 and Extended Data Figs 4, 5) . b, Immunoblot confirming successful transduction of the MM3MG cell line with Her2 and Pgr-B. Note that transduction of PGRB increases HER2 levels. c, d, Overexpression of Pgr-B in MM3MG cells (MM3MGPgrB) reduces migration, whereas Her2 overexpression (MM3MG-Her2) increases migration of cells. Addition of progesterone does not alter migration of Pgr-Boverexpressing cells (MM3MG-PgrB). e, Overexpression of Pgr-B in MM3MG cells reduces sphere formation, whereas Her2 overexpression increases sphere formation. c-e, Migrating/ sphere forming cells are not from the PGR + , but the PGR − population, which are responsive to PIPS. f-j, To investigate which PGR − cells were the target population of progesterone signalling, we exposed parental MM3MG cells and Her2transduced cells to progesterone, PIPS or mixed the cells with PGR + cells (only for migration experiments). Progesterone, WNT4 and RANKL, and coculture with MM3MG-PgrB induced sphere formation and migration of MM3MG cells, but decreased these responses in MM3MG-Her2 cells. k, Overexpression of Her2 increases proliferation of MM3MG cells (MM3MG-Her2). WNT4 and RANKL (WR) further increase proliferation of MM3MG-Her2 cells, but decreases proliferation of the parental (MM3MG) cells. Therefore based on expression of HER2, cells either migrate (HER2 low/− ) or proliferate (HER2 high ). l, WNT4 and RANKL treatment induces proliferation of primary cultured cells derived from primary tumours, but reduces it in cells derived from early lesions. m, Reduction of HER2 signalling by lapatinib overrides the inhibitory effect of WNT4 and RANKL, and increases migration in MM3MG-Her2 cells. However, strong inhibition of HER2 signalling reduces migration. n, Lapatinib inhibits HER2 signalling by preventing phosphorylation. o, Cells that migrated through the pores of the migration chamber insert were stained for HER2 (FITC, green) and PGR or ERα (Cy3, red). In 1:1 coculture of MM3MG-PgrB and MM3MG-Her2 (top) only HER2 expressing cells migrate. Migrated primary cells derived from early lesions (middle) do not express PGR and display faint HER2 staining (brightness of HER2 and PGR staining increased by 50% for better visibility). HER2 and PGR doublepositive T47D cells fixed onto the filters of migration chambers served as positive control of staining. m-o, Cells with low/ intermediate signalling of HER2 show the highest response in migration and sphere formation induction by PIPS. * P ≤ 0.05; * * P ≤ 0.01; * * * P ≤ 0.001; * * * * P ≤ 0.0001; NS, not significant; (Ftest of the slope (k, l) or Student's ttest (other panels)); data are mean ± s.d. For gel source data, see Supplementary Fig. 1 . To investigate whether human breast cancer cells display similar regulatory circuits as found in mouse cells, we selected 16 cell lines of different breast cancer subtypes. a, HER2 mRNA expression levels in 15 human cell lines compared to the hTERTHME cell line. Different colours indicate the subtype of breast cancer of each cell line. b, The expression of miR95p in human breast cancer cell lines compared to hTERTHME cells. Note that cell lines highly expressing HER2 (see a) express more miR95p similar to primary tumours of BALBNeuT and TUBO cells (see Fig. 3b, c) , whereas two HER2 high / PGR high cell lines, BT474 and T47D, do not express miR95p similar to human HER2 high /PGR high samples (see Fig. 5d ). c, High cell density leads to upregulation of HER2 mRNA (top) or protein levels (bottom) in several cell lines. Only four cell lines were analysed for protein level (HER2 level was not influenced by cell density in CAMA1; HER2 level regulated by cell density in HCC1806, MDAMB231 and MCF7). Numbers below the blots denote fold change of HER2 in high density compared to low density normalized over β actin. d, Expression of miR95p is upregulated by cell density in SKBR3, HCC1937, HCC1806 and MCF7 cell lines. e, Migration and sphereforming potential of 10 out of 16 cell lines grown at low and high densities, and treated with PIPS or progesterone. The first 7 cell lines regulate HER2 transcripts by density (see c) and their response to PIPS is similar to TUBO cells and primary mammary cell cultures of BALBNeuT mice (see Fig. 2 and Extended Data Fig. 4l, m) . The remaining three cell lines do not regulate HER2 transcripts by cell density, but respond to progesterone similarly to the TUBO cell line and primary mammary cell cultures of BALBNeuT mice (see Fig. 2 and Extended Data Fig. 4l, m) . We did not perform functional assays with BT549 (triple negative subtype), T47D (luminal, MCF7like), MDAMB175, ZR751 (luminal, CAMA1 like), hTERTHME (transformed normal, similar to MCF10A) because of breast cancer subtype redundancy or poor growth (HCC1569). y axes show the percentage of migrating cells (left) and observed spheres (right) relative to seeded cells. Data are mean ± s.d. For gel source data, see Supplementary Fig. 1 . 

Extended Data Figure 10 | PGR, HER2 signalling and dissemination in breast cancer patients. a, Double staining of a HER2 high /PGR high human breast cancer sample (PGR, brown, nucleus; HER2, red/pink, membrane). Cells with varying expression levels of HER2 and PGR, as well as negative, single or doublepositive cells can be seen. Scale bar, 100 μ m. Arrows indicate, doublepositive (DP), doublenegative (DN) and singlepositive (SP) cells. b, Lack of PGR expression in highdensity areas of HER2 high / PGR high classified tumour samples (see Fig. 5c ) is directly linked to high miR95p and miR30a5p expression. Data are mean ± s.d.
